Rights Issue Information Booklet
Released
Released
Announcement PDF
INVION LIMITED
ACN 094 730 417
Information Booklet
1 for 20 pro rata non-renounceable Entitlement Offer at 7.5 cents per Share
to raise approximately $2 million before Offer Costs.
Entitlement Offer closes: 5.00pm (AEDT) on 25 March 2014
If you are an Eligible Shareholder, this is an important document that requires your immediate attention.
It should be read in its entirety. If, after reading this document you have any questions about the
securities being offered for issue under it or any other matter, you should contact your stockbroker,
solicitor, accountant or other professional adviser.
Joint Lead Managers
Legal Adviser
IMPORTANT NOTICES
This Information Booklet is dated 26 February 2014.
Capitalised terms in this section have the meaning given to
them in this Information Booklet.
The Entitlement Offer is being made without a prospectus in
accordance with section 708AA Corporations Act (as
notionally modified by ASIC Class Order 08/35). This
Information Booklet does not contain all of the information
which a prospective investor may require to make an
informed investment decision. The information in this
Information Booklet does not constitute financial product
advice and does not take into account your investment
objectives, financial situation or particular needs.
This Information Booklet is important and should be read in its
entirety before deciding to participate in the Entitlement
Offer. This Information Booklet is not a prospectus under the
Corporations Act and has not been lodged with ASIC.
By returning an Entitlement and Acceptance Form or
otherwise paying for your New Shares or Top Up Shares
through BPAY in accordance with the instructions on the
Entitlement and Acceptance Form, you acknowledge that
you have read this Information Booklet and you have acted
in accordance with and agree to the terms of the
Entitlement Offer detailed in this Information Booklet.
No overseas offering
This Information Booklet and the accompanying Entitlement
and Acceptance Form do not constitute an offer or
invitation in any place in which, or to any person to whom, it
would not be lawful to make such an offer or invitation. This
Information Booklet is not to be distributed in, and no offer of
New Shares or Top Up Shares is to be made in countries other
than Australia and New Zealand. The distribution of this
Information Booklet in other jurisdictions may be restricted by
law and therefore persons who come into possession of this
Information Booklet should seek advice on and observe any
such restrictions. Any failure to comply with such restrictions
may constitute a violation of applicable securities laws.
No action has been taken to register or qualify the
Entitlement Offer, the Entitlements or the New Shares, or
otherwise permit the public offering of the New Shares, in
any jurisdiction outside Australia or New Zealand. Foreign
exchange control restrictions or restrictions on remitting funds
from your country to Australia may apply. Your Application
for New Shares is subject to all requisite authorities and
clearances being obtained for Invion to lawfully receive your
Application Monies.
New Zealand
The New Shares are not being offered or sold to the public
within New Zealand other than to existing shareholders of the
Company with registered addresses in New Zealand to
whom the offer of New Shares is being made in reliance on
the Securities Act (Overseas Companies) Exemption Notice
2013 (New Zealand).
This document has not been registered, filed with or
approved by a New Zealand regulatory authority under the
Securities Act 1978 (New Zealand). This document is not an
investment statement or prospectus under New Zealand law
and is not required to, and may not, contain all the
information that an investment statement or prospectus
under New Zealand law is required to contain.
Definitions, currency and time
Defined terms used in this Information Booklet are contained
in section 5. All references to currency are to Australian
dollars and all references to time are to Australian Eastern
Daylight Saving Time (AEDT), unless otherwise indicated.
Taxation
There will be tax implications associated with participating in
the Entitlement Offer and receiving New Shares. Invion
considers that it is not appropriate to give advice regarding
the tax consequences of subscribing for New Shares under
this Information Booklet or the subsequent disposal of any
New Shares. Invion recommends that you consult your
professional tax adviser in connection with the Entitlement
Offer.
Privacy
Invion collects information about each Applicant provided
on an Entitlement and Acceptance Form for the purposes of
processing the Application and, if the Application is
successful, to administer the Applicant's shareholding in
Invion. By submitting an Entitlement and Acceptance Form,
you will be providing personal information to Invion (directly
or through the Share Registry). Invion collects, holds and will
use that information to assess your Application. Invion
collects your personal information to process and administer
your shareholding in Invion and to provide related services to
you. Invion may disclose your personal information for
purposes related to your shareholding in Invion, including to
the Share Registry, Invion's related bodies corporate, agents,
contractors and third party service providers, including
mailing houses and professional advisers, and to ASX and
regulatory bodies. You can obtain access to personal
information that Invion holds about you. To make a request
for access to your personal information held by (or on behalf
of) Invion, please contact Invion through the Share Registry.
Governing law
This Information Booklet, the Entitlement Offer and the
contracts formed on acceptance of the Applications are
governed by the law applicable in Queensland, Australia.
Each Applicant submits to the exclusive jurisdiction of the
courts of Queensland, Australia.
No representations
No person is authorised to give any information or to make
any representation in connection with the Entitlement Offer
which is not contained in this Information Booklet. Any
information or representation in connection with the
Entitlement Offer not contained in the Information Booklet
may not be relied upon as having been authorised by Invion
or any of its officers.
Past Performance
Investors should note that Invion’s past performance,
including past share price performance, cannot be relied
upon as an indicator of (and provides no guidance as to)
Invion’s future performance including Invion’s future financial
position or share price performance.
Future performance
This Information Booklet contains certain forward-looking
statements with respect to the financial condition, results of
operations, projects and business of Invion and certain plans
and objectives of the management of Invion. These
forward-looking statements involve known and unknown
risks, uncertainties and other factors which are subject to
change without notice, and may involve significant elements
of subjective judgement and assumptions as to future events
which may or may not be correct.
Forward-looking statements are provided as a general guide
only and there can be no assurance that actual outcomes
will not differ materially from these statements. Neither
Invion, nor any other person, gives any representation,
warranty, assurance or guarantee that the occurrence of
the events expressed or implied in any forward-looking
statement will actually occur. In particular, such forwardlooking statements are subject to significant uncertainties
and contingencies, many of which are outside the control of
Invion. A number of important factors could cause actual
results or performance to differ materially from the forward
looking statements. Investors should consider the forward
looking statements contained in this Information Booklet in
light of those disclosures.
Risks
Refer to section 4 of this Information Booklet for a summary of
general and specific risk factors that may affect Invion.
2
Chairman’s and Managing Director’s letter
Dear Shareholder
On behalf of Invion Limited (Invion), we are very pleased to invite you to participate in the recently
announced 1 for 20 non-renounceable entitlement issue for new Invion ordinary shares (New Shares)
at an issue price of 7.5 cents per New Share (Entitlement Offer).
On 21 February 2014, Invion announced its successful raising of approximately $5 million through a
placement to institutional and sophisticated investors (Placement) and its intention to proceed with
the Entitlement Offer (together, the Equity Raising).
Funds raised from the Equity Raising will be applied to the recently announced collaboration with 3M
Drug Delivery Systems to develop Invion’s inhaled respiratory drugs franchise, and the continuing
development of Invion’s three drug assets:
INV102 (nadolol);
INV103 (ala-Cpn10); and
INV104 (zafirulkast).
More detailed information on the use of funds from the Equity Raising can be found in section 1.2 of
this Information Booklet.
Your Company’s focus continues to be the development and commercialisation of new therapies for
inflammatory diseases, and we are continuing to build on a strong body of evidence for our
proprietary therapeutic candidates.
Our three phase II clinical programs – in chronic bronchitis, asthma and lupus – are all underway.
Your Company’s achievements in the last 12 months include:
-
Initiation and commencement of our phase II clinical trial of INV102 (nadolol) in asthma
patients, a study that is funded by the US National Institutes of Health in excess of US$4 million;
The submission of an Investigational New Drug Application (IND) with the US Food and Drug
Administration (FDA) for our INV103 (ala-Cpn10) program in lupus;
Attracting high calibre biotech CEO, Dr Greg Collier;
Initiation and commencement of our phase II clinical trial investigating INV103 (ala-Cpn10) in
lupus patients;
Initiation and commencement of our phase II clinical trial investigating INV102 (nadolol) in
patients with chronic obstructive pulmonary disease (COPD) who are in registered quit
smoking programs; and
The announcement of a global licensing deal to develop inhaled versions of Accolate,
adding a new asset, INV104 (zafirlukast) to our pipeline, as the Company seeks to develop the
first inhaled, non-steroidal, anti-inflammatory treatment for asthma.
Further, we are very pleased to have commenced a collaboration to progress our inhaled respiratory
drug franchise with 3M Drug Delivery Systems, a global leader in pressured metered dose inhaler
(PMDI) technology.
This collaboration kick starts the next phase of Invion’s strategic development and growth, and was a
catalyst for the Equity Raising.
Inhaled respiratory drugs may provide advantages over other delivery methods due to their targeted
delivery, smaller doses and fewer side effects. If Invion’s inhaled treatments prove safe and effective
in patients, your Company will have the opportunity to target the multi billion dollar respiratory market
with three potential drug candidates – oral INV102, inhaled INV102 and inhaled INV104.
3
We continue to believe that if INV102 (nadolol) shows a positive effect and reduces or reverses mucus
metaplasia in the airway, we have an asset with significant potential that could have a positive
impact on patients worldwide.
We have continued to progress our programs cost-effectively, and have aimed to secure further
sources of non-dilutive funding for future development programs. We also continue to build
relationships with strategic partners, and similar to the Company’s agreements with Numoda
Corporation and 3M, continue to identify opportunities for collaboration with leading global
companies.
The Company’s plans and target clinical milestones for the coming 12-18 months include completion
of three phase II clinical trials currently underway in asthma, ‘smoking cessation’ and lupus. We will
also be progressing the inhaled respiratory franchise through feasibility and early manufacture
towards early clinical, pre-IND and IND status. The Company’s forthcoming clinical milestones are
described in more detail in the Invion investor presentation lodged with the Australian Securities
Exchange (ASX) on 26 February 2014 (and set out in section 2 of this Information Booklet).
Under the Entitlement Offer, Eligible Shareholders have the opportunity to invest at the price of 7.5
cents, which is the same price as the institutional investors who participated in the Placement. The
number of New Shares you are entitled to subscribe for under the Entitlement Offer (Entitlement) is set
out in your personalised Entitlement and Acceptance Form that is enclosed in this Information Booklet.
The issue price of 7.5 cents per New Share represents a 20% discount to the weighted average closing
price for the five trading days to 18 February 2014 (being the last trading day before the Placement
was announced by the Company). If you take up your Entitlement, you can also apply for additional
shares under a ‘top-up’ facility (refer to section 3 of this Information Booklet for more information).
Eligible Shareholders may subscribe for all or part of their Entitlement. Any New Shares not taken up by
the Closing Date may be made available to those Eligible Shareholders who took up their full
Entitlement and applied for additional New Shares under the Top Up Facility detailed in section 3.
There is no guarantee that such Shareholders will receive the number of New Shares applied for under
the Top Up Facility, or any.
The Entitlement Offer is non-renounceable and therefore your Entitlements will not be tradeable on
the ASX or otherwise transferable. We encourage you to consider this offer carefully.
Invion Directors will take up all or part of their entitlement.
Your Board recommends this offer of New Shares for your consideration.
Other Information
This Information Booklet contains important information, including:
the investor presentation referred to above, which was released to the ASX on 26 February
2014, and provides information on Invion for you to consider;
instructions on how to apply, detailing how to participate in the Entitlement Offer if you
choose to do so, and a timetable of key dates;
a personalised Entitlement and Acceptance Form which details your Entitlement, to be
completed in accordance with the instructions; and
instructions on how to take up all or part of your Entitlement via BPAY.
The Entitlement Offer closes at 5.00pm (AEDT) on 25 March 2014.
Please read in full the details on how to submit your application, which are set out in this Information
Booklet. For further information regarding the Entitlement Offer, please call the Share Registry, Link
Market Services on 1300 910 051 (within Australia) or +61 1300 910 051 (outside Australia), or visit the
Company’s website at www.inviongroup.com.
An investment in Invion should be considered speculative. Section 4 identifies the major risks
associated with an investment in Invion. You should consult your stockbroker, solicitor, accountant or
other professional adviser to evaluate whether or not to participate in the Entitlement Offer.
4
On behalf of the Board of Invion, we encourage you to consider this investment opportunity and
thank you for your ongoing support.
Yours sincerely
Dr Ralph Craven
Chairman
26 February 2014
Dr Greg Collier
Managing Director & Chief Executive Officer
26 February 2014
5
Summary of Equity Raising
Placement
Issue Price
7.5 cents per Share
Size
66,666,671 million Shares
Gross proceeds
Approximately $5 million
Entitlement Offer
Ratio
1 New Share for every 20 Existing Shares
Issue Price
7.5 cents per New Share
(i)
Size
Up to 26,468,823 million New Shares
(ii)
Gross proceeds
Approximately $2 million
(iii)
Total gross proceeds of the
Equity Raising
Approximately $7 million
Capital structure
Subject to rounding up of fractional Entitlements, the capital structure of Invion following the issue of
New Shares is expected to be as follows:
(iv)
Shares on issue as at 21 February 2014 (announcement of the Placement)
462,709,792
Shares issued under the Placement
66,666,671
New Shares to be issued under the Entitlement Offer
26,468,823
Shares on issue after the Equity Raising
555,845,286
Placement
Investors who receive Shares under the Placement will have those Shares registered by the Record
Date and will be entitled to participate in the Entitlement Offer as Eligible Shareholders.
Risks
The Directors believe the primary risks associated with an investment in Invion are:
Clinical trial risk - Invion’s ability to obtain regulatory approval for its products and profitably
commercialise its products is dependent upon its ability to conduct successful clinical trials
which are inherently risky, depend upon the availability of patients and regulatory approvals,
and have no guarantee of returning efficacious results or proving practical or cost effective.
Regulatory and reimbursement approval risk – Invion’s ability to research, develop,
manufacture and sell its products is dependent upon regulatory approvals in target markets,
for which there is no guarantee of securing such approvals in a timely and cost effective
manner. While submissions may be made for reimbursement in certain jurisdictions, there is no
guarantee that Invion will be reimbursed for any costs associated with developing its
products, which may adversely impact its financial position.
Toxicology – In parallel with clinical trials, Invion will continue to test its product candidates in
animal species under controlled conditions governed by Good Laboratory Practices (GLP)
and its equivalent regulations under the International Committee on Harmonisation (ICH).
These studies could generate results that identify previously unknown safety concerns, limit the
use of product candidates to certain patient populations, or limit the doses that may be used
below the doses needed to achieve efficacy.
6
Delay risk – the potential for delay of any of the key milestones, presents a number of risks,
including the ability to secure a commercial partner, receive regulatory classification and
achieve revenues within estimated timeframes.
Manufacturing and distribution capability risk – Invion’s ultimate success is dependent upon its
ability, or that of its commercial partners, to scale up and maintain production within the
estimated time frame, and in accordance with regulatory standards.
Competition – Invion is aware that there are a number of products in development or recently
approved for the treatment of autoimmune diseases, including lupus, as well as airway
diseases including asthma and chronic bronchitis. One or more of these competitor products
or product candidates may be sufficiently safe and effective so as to minimize the real or
perceived value of Invion product candidates, thereby negatively affecting the value placed
upon our products for licensing or partnering.
Funding risk – The development of the respiratory franchise which includes progress to phase III
clinical trials for oral INV102(nadolol) in smoking cessation; plus the development of two
inhaled drugs (INV102 & INV104) are the primary drivers of cash requirements in the coming
2/3 years. It is estimated $10-20M will be required to complete phase III oral INV102, and reach
phase II in the inhaled INV102 and inhaled INV104 programs. To the extent the Company does
not find an appropriate partner for its programs, it may need to raise further funds, which may
not be available when required or only available on unfavourable terms.
These are a summary of some of the potential risks associated with an investment in Invion. Before
making a decision to invest, you should read section 4 which further details key risks.
Key dates
Activity
Date
Announcement of the Entitlement Offer
26 February 2014
Mailing of the Entitlement Offer details
27 February 2014
Ex date
28 February 2014
Record Date for Entitlement Offer (7.00pm (AEDT))
6 March 2014
Information Booklet and Entitlement & Acceptance Form despatched
10 March 2014
Entitlement Offer opens
11 March 2014
Closing date for acceptances under Entitlement Offer (5.00pm (AEDT))
25 March 2014
New Shares quoted on deferred settlement basis
26 March 2014
Company notifies ASX of under subscriptions
28 March 2014
Allotment of New Shares under the Entitlement Offer
2 April 2014
Despatch of holding statements for New Shares issued under
the Entitlement Offer
3 April 2014
Normal ASX trading for New Shares issued under the Entitlement Offer
commences
3 April 2014
This timetable is indicative only and subject to change. The Directors may vary these dates, in consultation with
the Joint Lead Managers, subject to the Listing Rules. An extension of the Closing Date will delay the anticipated
date for issue of the New Shares.
The Directors also reserve the right not to proceed with the whole or part of the Entitlement Offer any time prior to
allotment and issue of the New Shares. In that event, the relevant Application Monies (without interest) will be
returned in full to Applicants.
7
Enquiries
Telephone: 1300 910 051 (within Australia) or +61 1300 910 051 (outside Australia) between 8.30am and
5.30pm (AEDT) Monday to Friday. Alternatively, contact your stockbroker, solicitor, accountant or
other professional adviser.
If you have lost your Entitlement and Acceptance Form and would like a replacement form, you
should contact the Share Registry on the above telephone numbers.
8
Table of contents
Chairman’s and Managing Director’s letter ------------------------------------------------------------------- 3
Summary of Equity Raising ------------------------------------------------------------------------------------- 6
Key dates -------------------------------------------------------------------------------------------------------- 7
Enquiries ---------------------------------------------------------------------------------------------------------- 8
1
Description and effect of the Offer ------------------------------------------------------------------- 10
1.1
Overview
10
1.2
Purpose of the Placement and the Entitlement Offer
13
1.3
Joint Lead Managers
14
1.4
Eligibility of Shareholders
14
1.5
Ranking of New Shares
14
1.6
Allotment
14
1.7
Information availability
14
2
Investor presentation ---------------------------------------------------------------------------------- 15
3
How to Apply ------------------------------------------------------------------------------------------ 30
4
3.1
Shareholder’s choices
30
3.2
Taking up all of your Entitlement and participating in the Top Up Facility
30
3.3
Taking up part of your Entitlement and allowing the balance to lapse
31
3.4
Allow your Entitlement to lapse
31
3.5
Consequences of not accepting your Entitlement
31
3.6
Payment and refunds
31
3.7
Entitlement and Acceptance Form is binding
31
3.8
Notice to nominees and custodians
32
Risk factors --------------------------------------------------------------------------------------------- 33
4.1
Introduction
33
4.2
Specific risks
33
4.3
General market risks
36
5
Definitions ---------------------------------------------------------------------------------------------- 38
6
Corporate information -------------------------------------------------------------------------------- 40
9
1
Description and effect of the Offer
1.1
Overview
The Entitlement Offer is a non-renounceable offer of approximately 26.5 million New Shares at
7.5 cents per New Share to raise approximately $2 million (before Offer Costs).
The proceeds of the Equity Raising will allow Invion to proceed with:
1
Project initiation and commencement of works with 3M Drug Delivery Systems to
assess the feasibility of INV102 (nadolol) as an inhaled treatment for chronic
obstructive pulmonary disease and cystic fibrosis.
2
Project initiation and commencement of works with 3M Drug Delivery Systems to
assess the feasibility of INV104 (zafirlukast) as an inhaled treatment for asthma.
3
Ongoing phase II trials in COPD, asthma and systemic lupus erythematosus (lupus)
including data analysis.
4
Ongoing working capital, including clinical research team, administration,
compliance, and intellectual property prosecution.
Eligible Shareholders are entitled to acquire 1 New Share for every 20 Shares held on the
Record Date (Entitlement). The issue price of 7.5 cents per New Share represents a discount of
20% to the weighted average closing price for the five trading days to 18 February 2014
(being the last trading day before the Placement was announced by the Company).
Fractional Entitlements will be rounded up to the nearest whole number of New Shares.
The Entitlement Offer is non-renounceable. Accordingly, Entitlements do not trade on the
ASX, nor can they be transferred or otherwise disposed of.
An Entitlement and Acceptance Form setting out your Entitlement accompanies this
Information Booklet.
Shareholders will have their interest in Invion diluted because of the issue of Shares under the
Placement. In addition, Eligible Shareholders who do not take up all of their Entitlements will
have their percentage shareholding in Invion further diluted.
Eligible Shareholders should be aware that an investment in Invion involves risks and should be
considered speculative. The key risks identified by Invion are identified in section 4 of the
Information Booklet.
Top Up Facility
Eligible Shareholders may subscribe for all or part of their Entitlement.
Any New Shares not taken up by the Closing Date may be made available to those Eligible
Shareholders who took up their full Entitlement and applied for additional New Shares under
the Top Up Facility detailed in section 3.
There is no guarantee that such Shareholders will receive the number of New Shares applied
for under the Top Up Facility, or any.
There is no cap on the number of additional New Shares that Eligible Shareholders may apply
for under the Top Up Facility, although the number of New Shares available under the Top Up
Facility will not exceed the shortfall from the Entitlement Offer. The Directors reserve the right
to allot and issue New Shares under the Top Up Facility at their discretion.
10
Options
The Company has 29,850,000 existing options on issue, comprising:
Category
Number
Exercise Price
Lapse Date
Exercisable at Record
Date
Directors
5,000,000
3,000,000 at $0.09
9 November 2017
2,000,000 at $0.10
Employees and
consultants
630,000
Other
1,700,000
Subtotal
7,330,000
525,000 at $0.09
9 November 2017
105,000 at $0.10
$0.517
16 May 2015
12,000,000 at $0.09
9 November 2017
Not exercisable at
Record Date
Directors
20,000,000
8,000,000 at $0.10
Employees and
consultants
2,520,000
Subtotal
22.520,000
Total options on issue
29,850,000
2,100,000 at $0.09
9 November 2017
420,000 at $.010
The Company does not expect the options identified as exercisable to be exercised prior to
the Record Date.
In addition, the Company intends to issue approximately 14,000,000 options to employees
and consultants to the Company, under its Executive and Employee Share Option Plan. Any
issue of options to directors will be subject to shareholder approval.
Effect on the Company’s financial position
Set out below is the Pro Forma Statement of Financial Position of the Company as at 31
December 2013. This statement comprises the Reviewed Statement of Financial Position as at
31 December 2013 adjusted for the Equity Raising (assuming that the Entitlement Offer is fully
subscribed) as detailed under the heading ‘Pro Forma Adjustments’ below:
11
Dec-13
Placement
Rights Issue
$
Pro forma
$
ASSETS
CURRENT ASSETS
Cash and cash equivalents
1,865,061
Trade and other receivables
658,968
658,968
52,893
2,576,922
52,893
9,155,922
Trade and other receivables
69,640
69,640
Property, plant and equipment
21,790
21,790
Intangible assets
TOTAL NON-CURRENT ASSETS
10,867,062
10,958,492
10,867,062
10,958,492
TOTAL ASSETS
13,535,414
20,074,414
Trade and other payables
909,689
909,689
Financial liabilities
16,764
16,764
Short-term provisions
TOTAL CURRENT LIABILITIES
70,988
997,441
70,988
997,441
Deferred tax liabilities
4,146,825
4,146,825
Long-term provisions
TOTAL NON-CURRENT LIABILITIES
11,028
4,157,853
11,028
4,157,853
Other current assets
TOTAL CURRENT ASSETS
4,677,000
1,862,000
8,404,061
NON-CURRENT ASSETS
LIABILITIES
CURRENT LIABILITIES
NON-CURRENT LIABILITIES
TOTAL LIABILITIES
5,155,294
5,155,294
NET ASSETS
8,380,120
14,919,120
EQUITY
Issued capital
107,513,313
Reserves
20,334,392
20,334,392
(119,467,585)
8,380,120
(119,467,585)
14,919,120
Accumulated losses
TOTAL EQUITY
4,677,000
1,862,000
114,052,313
Notes to the Pro Forma Consolidated Statement of Financial Position
Note 1: Pro Forma Adjustments
The Pro Forma Consolidated Statement of Financial Position has been prepared on the basis
that the following significant transactions occurred as at 31 December 2013:
Material transactions since 31 December 2013:
a.
the issue of 66,666,671 Shares under the Placement, raising gross proceeds of
approximately $5 million less expenses of $323,000
The Entitlement Offer:
b.
the issue of 26,468,823 New Shares under the Entitlement Offer, expected to raise gross
proceeds of approximately $2 million less estimated Offer Costs of $138,000
12
Note 2: Cash and cash equivalents
The Company’s pro forma cash position at 31 December 2013 adjusted for the Equity Raising
(assuming that the Entitlement Offer is fully subscribed) is derived from actual cash as follows:
$
Cash as at 31 December 2013
Placement proceeds
Expenses of the Placement
Gross proceeds of the Entitlement Offer
Offer Costs of the Entitlement Offer
Pro forma cash balance
1,865,061
5,000,000
(323,00
Share your feedback
Discover